CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017)

Stebbing J.; Baranau Y.; Baryash V

首页> 外文期刊>Journal of Turbulence >CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017)

【24h】

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017)

机译：CT-P6与英国阳性乳腺癌的参考曲妥珠单抗：随机，双盲，主动控制，相3等价试验（Vol 18，PG 917,2017）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of Turbulence》 |2017年第8期|共1页
作者
Stebbing J.; Baranau Y.; Baryash V;
展开▼
作者单位

Imperial Coll London Div Canc Dept Surg &

Canc London England;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类流体力学;
关键词
入库时间 2022-08-20 10:25:28

相似文献

外文文献
中文文献

1. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017) [J] . Stebbing J., Baranau Y., Baryash V The lancet oncology . 2017,第8期

机译：CT-P6与英国阳性乳腺癌的参考曲妥珠单抗：随机，双盲，主动控制，相3等价试验（Vol 18，PG 917,2017）
2. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017) [J] . Stebbing J., Baranau Y., Baryash V Journal of Turbulence . 2017,第8期

机译：CT-P6与英国阳性乳腺癌的参考曲妥珠单抗：随机，双盲，主动控制，相3等价试验（Vol 18，PG 917,2017）
3. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017) [J] . Stebbing J., Baranau Y., Baryash V Journal of Turbulence . 2017,第9期

机译：CT-P6与英国阳性乳腺癌的参考曲妥珠单抗：随机，双盲，主动控制，相3等价试验（Vol 18，PG 917,2017）
4. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
5. Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial [O] . F. J. Esteva, Y. V. Baranau, V. Baryash, -1

机译：CT-P6与参考曲妥珠单抗在HER2阳性早期乳腺癌中的疗效和安全性：一项3期随机试验的更新结果
6. CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial [O] . Stebbing, J, Baranau, Y, Baryash, V, 2017

机译：CT-p6与参考曲妥珠单抗相比HER2阳性乳腺癌：随机，双盲，主动控制，3期等效试验

CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial (vol 18, pg 917, 2017)

著录项

相似文献

相关主题

期刊订阅